Emcure Pharmaceuticals and Roche Sign Distribution Agreement in India

Emcure Pharmaceuticals Ltd has announced a distribution agreement with Roche to distribute select products in the nephrology and transplant medicine portfolio in India. The agreement, effective April 1, 2026, involves the distribution of Roche’s established brands, including CellCept®, Mircera®, and Neorecormon®. This collaboration is intended to expand patient access to therapies for chronic kidney disease (CKD) and transplant care across India.

The financial terms of the agreement have not been disclosed in the filing. However, the agreement involves the distribution of globally recognized brands in the nephrology and transplant segment. Emcure Pharmaceuticals will utilize its existing market presence in anemia management to distribute these products. The collaboration is expected to enhance the availability of critical therapies in the Indian market.

The scope of the agreement includes the distribution of CellCept®, a leading immunosuppressant used in organ transplants, and Mircera® and Neorecormon®, therapies for anemia in chronic kidney disease. Mircera® is noted for its long-acting erythropoiesis-stimulating agent (ESA) with dosing once every 2–4 weeks. Emcure’s role will involve leveraging its distribution network to ensure these products reach a wider patient base in India.

Emcure Pharmaceuticals is a market leader in anemia management and has a strong presence in the nephrology and chronic kidney disease segments. The addition of Roche’s nephrology and transplant portfolio complements Emcure’s existing offerings. This strategic alignment allows Emcure to expand its portfolio and provide these important medicines to a broader cross-section of patients across the country.

The agreement will be implemented starting April 1, 2026. Emcure Pharmaceuticals will be responsible for the distribution of Roche’s products in India. The collaboration is aimed at improving patient access to proven therapies while supporting better anemia management and long-term outcomes for patients with CKD and transplant needs.

Roche is a global leader in biotechnology with a differentiated product portfolio in oncology, rare diseases, ophthalmology, hematology, and diseases of the central nervous system. The company is committed to advancing the understanding and treatment of multiple high-burden disease areas to address unmet needs and help transform patients’ lives.

Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical company engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation and quality, Emcure focuses on improving patient health and well-being across several major therapeutic areas. Established in 1981, Emcure is ranked as the 13th largest pharmaceutical company in India in terms of domestic sales as of October 2025.